We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NIU:NASDAQNiu Technologies Analysis

Data as of 2026-08-24 - not real-time

$1.95

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Niu Technologies trades at $1.95, with its moving averages tangled rather than clearly stacked — a neutral trend structure. The last 30 days have lost 9.7%. Momentum indicators put RSI at 32.7 (approaching oversold) with MACD reading bearish. The recent range runs from support at $1.95 up to resistance at $2.74.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 30.4% above the current price. Revenue is growing at 14.7% on a -4.3% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 73.3%, a beta of 1.60 and a maximum drawdown of 64.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top Market Events

-- Second Quarter Revenues of RMB 1,440.4 million, up 14.7% year over year -- Second Quarter Net Loss of RMB 102.2...Eagle-Tribune1monNiu Technologies to Report Second Quarter 2026 Financial Results on August 10, 2026BEIJING, July 13,...Detailed price information for Niu Technologies ADR NIU-Q from The Globe and Mail including charting and trades.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 2.95
  • MACD momentum is negative
  • 30-day price change of -9.7%

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 2.95
  • Analyst targets imply +30.4% versus the current price
  • 30-day volatility of 73.3%

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Negative profit margin of -4.3%
  • Analyst targets imply +30.4% versus the current price
  • Negative return on equity of -25.0%

Key Metrics & Analysis

Financial Health

Revenue Growth14.70%
Profit Margin-4.29%
P/E Ratio-19.9
ROE-24.98%
ROA-4.63%
Debt/Equity30.99
P/B Ratio1.5

Technical Analysis

TrendNeutral
RSI32.7
Support$1.95
Resistance$2.74
MA 20$2.29
MA 50$2.26
MA 200$2.95
MACDBearish
VolumeIncreasing
Fear & Greed Index94.41

Valuation

Target Price$2.54
Upside/Downside30.41%
GradeFair
TypeBlend

Risk Assessment

Beta1.60
Volatility73.34%
Sector RiskHigh
Reg. RiskLow
Geo RiskHigh
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.